{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Patient&page=124",
    "query": {
      "intervention": "Patient",
      "page": 124
    },
    "page_size": 10
  },
  "pagination": {
    "page": 124,
    "page_size": 10,
    "total_count": 81002,
    "total_pages": 8101,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Patient&page=125&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Patient&page=123&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T02:20:04.121Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003239",
      "title": "Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Recombinant Interferon Alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Omacetaxine Mepesuccinate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "1998-03",
      "completion_date": "2001-10",
      "has_results": false,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003239"
    },
    {
      "nct_id": "NCT01797575",
      "title": "N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "N-acetyl-cysteine (NAC)",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Sugar Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2013-01",
      "completion_date": "2017-02-01",
      "has_results": true,
      "last_update_posted_date": "2018-04-30",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01797575"
    },
    {
      "nct_id": "NCT05325775",
      "title": "Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Post-menopausal Vasomotor Symptoms"
      ],
      "interventions": [
        {
          "name": "ACER-801 50 mg BID",
          "type": "DRUG"
        },
        {
          "name": "ACER-801 100 mg BID",
          "type": "DRUG"
        },
        {
          "name": "ACER-801 200 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acer Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 49,
      "start_date": "2022-03-30",
      "completion_date": "2023-03-04",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 1,
      "location_summary": "West Bend, Wisconsin",
      "locations": [
        {
          "city": "West Bend",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05325775"
    },
    {
      "nct_id": "NCT04807101",
      "title": "Sedation Regimens in GI Endoscopy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Anesthesia",
        "Endoscopy",
        "Colonoscopy",
        "Conscious Sedation"
      ],
      "interventions": [
        {
          "name": "midazolam alone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Greg S Cohen MD LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 300,
      "start_date": "2021-04-05",
      "completion_date": "2023-07-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-15",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04807101"
    },
    {
      "nct_id": "NCT04320381",
      "title": "Qualitative Understanding of Experiences With the SIMPLIFY Trial",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis",
        "Drug Withdrawal"
      ],
      "interventions": [
        {
          "name": "Qualitative Interview",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2020-12-23",
      "completion_date": "2022-09-16",
      "has_results": false,
      "last_update_posted_date": "2023-08-25",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04320381"
    },
    {
      "nct_id": "NCT02900781",
      "title": "Comparative Effectiveness of an Activity-specific Monitoring Device- StepRite",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoarthritis",
        "Degenerative Joint Disease"
      ],
      "interventions": [
        {
          "name": "Steprite™",
          "type": "DEVICE"
        },
        {
          "name": "Standard of care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Texas Tech University Health Sciences Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2016-10-21",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2019-08-09",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 1,
      "location_summary": "Lubbock, Texas",
      "locations": [
        {
          "city": "Lubbock",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900781"
    },
    {
      "nct_id": "NCT01145430",
      "title": "Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "Male Breast Carcinoma",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pegylated Liposomal Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2010-06-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 6,
      "location_summary": "New York, New York • The Bronx, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01145430"
    },
    {
      "nct_id": "NCT02878928",
      "title": "Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression",
        "Anxiety"
      ],
      "interventions": [
        {
          "name": "IDgenetix Neuropsychiatric Test Panel",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "AltheaDx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 579,
      "start_date": "2016-05",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-19",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 17,
      "location_summary": "Rolling Hills, California • San Diego, California • Torrance, California + 13 more",
      "locations": [
        {
          "city": "Rolling Hills",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Lauderhill",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02878928"
    },
    {
      "nct_id": "NCT06609928",
      "title": "FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Refractory Childhood Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "FOLR1 CAR T-cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Pheresis",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "Up to 6 Years"
      },
      "enrollment_count": 12,
      "start_date": "2025-02-24",
      "completion_date": "2042-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06609928"
    },
    {
      "nct_id": "NCT02059265",
      "title": "Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Clear Cell Adenocarcinoma",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Cancer"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 35,
      "start_date": "2014-02-14",
      "completion_date": "2023-06-26",
      "has_results": true,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-11-22T02:20:04.121Z",
      "location_count": 227,
      "location_summary": "Anchorage, Alaska • Auburn, California • Berkeley, California + 154 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Auburn",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02059265"
    }
  ]
}